Inactive Instrument

Spring Bank Pharmaceuticals, Inc. Stock price

Equities

SBPH

US8494311017

Dynamic Chart
Spring Bank Pharmaceuticals, Inc. has Changed its Name to F-star Therapeutics, Inc CI
F-Star Therapeutics Limited completed the acquisition of Spring Bank Pharmaceuticals, Inc. in a reverse merger transaction. CI
Spring Bank Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2020 CI
Spring Bank Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2020 CI
Transcript : Spring Bank Pharmaceuticals, Inc., F-Star Therapeutics Limited - M&A Call
F-Star Therapeutics Limited entered into a definitive agreement to acquire Spring Bank Pharmaceuticals, Inc. for $90.6 million in a reverse merger transaction. CI
Spring Bank Pharmaceuticals, Inc.(NasdaqCM:SBPH) dropped from Russell Microcap Value Index CI
Spring Bank Pharmaceuticals, Inc.(NasdaqCM:SBPH) dropped from Russell Microcap Growth Index CI
Spring Bank Pharmaceuticals, Inc.(NasdaqCM:SBPH) dropped from Russell Microcap Index CI
Transcript : Spring Bank Pharmaceuticals, Inc. - Shareholder/Analyst Call
Spring Bank Pharmaceuticals, Inc. Advances IV SB 11285 Clinical Program CI
Spring Bank Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2020 CI
Spring Bank Pharmaceuticals, Inc. Announces Management Changes CI
Spring Bank Pharmaceuticals, Inc. Announces New Clinical Collaboration with Roche CI
Spring Bank Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2019 CI
More news
Spring Bank Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of a class of therapeutics for the treatment of viral infections, inflammatory diseases and cancers using its small molecule nucleotide platform. The Company is developing its product inarigivir soproxil (inarigivir), for the treatment of chronic hepatitis B virus (HBV). The Company's inarigivir selectively activates within infected hepatic cells the cellular protein, retinoic acid-inducible gene 1 (RIG-I), to inhibit viral replication and to cause the induction of intracellular interferon signaling pathways for antiviral defense. The Company also developing a second STING (STimulator of INterferon Genes) agonist product candidate, SB 11285, which is an immunotherapeutic agent for the potential treatment of selected cancers. The Company lead product is inarigivir.
Sector
-
More about the company
  1. Stock
  2. Equities
  3. Stock Spring Bank Pharmaceuticals, Inc. - Nasdaq